Market Scope provides comprehensive coverage of the ophthalmic market. Our news stories are a combination of public and proprietary content ranging from coverage of international meetings, surgeon survey results and trends, analysis of company financial reports and public medical registries, press releases, and interviews with executives. Register today to receive free weekly email updates, our top data chart, surgeon poll results, and much more. Locked content can be accessed through a subscription to our ophthalmic industry newsletters.
France’s Nicox reported Dec. 4 that its partner Ocumension Therapeutics had made the first commercial sale of Zerviate (cetirizine ophthalmic solution) 0.24% in China. Zerviate is indicated for ocu...
Harrow, of Nashville, Tennessee reported Nov. 13 that it had entered into a partnership with GoodRx to provide patients for whom insurance is not a viable option a cash-pay alternative. Harrow prod...
Market Scope is tracking companies that have announced clinical trial updates or milestone achievements.
France’s Nicox announced Sept. 18 that partner Ocumension Therapeutics had received regulatory approval in China to commercialize Nicox’ Zerviate (cetirizine ophthalmic solution) 0.24% for ocular i...
AbbVie has introduced two new preservative-free lubricant eye drop products—Refresh Tears PF and Refresh Relieva PF Xtra. AbbVie, of North Chicago, Illinois, said the new products feature a soft-sq...
Market Scope is tracking companies that have announced new candidates to diagnose and treat eye disease.
Shanghai-based AffaMed Therapeutics announced Feb. 19 that the Singapore Health Sciences Authority had accepted its new drug application (NDA) for Dextenza (0.4 mg dexamethasone intracanalicular in...
Harrow reported Feb. 15 that it had licensed to Apotex exclusive marketing and distribution rights to Verkasia and over-the-counter Cationorm Plus in the Canadian market. In addition, Apotex will p...
Indian drugmaker Lupin announced Dec. 27 that the US FDA had approved its abbreviated new drug application for loteprednol etabonate ophthalmic suspension, 0.2%, a generic equivalent of Bausch + Lo...
A corporate account gives you access to licensed reports and subscriptions, the latest news, a personalized dashboard, and weekly emails with news and data.